A ferritin-based mosaic-like nanovaccine elicits effective cross-protection against H1N1 and H3N2 swine influenza viruses
Open Access
- 31 May 2026
- journal article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Abstract
Swine influenza viruses (SIVs), particularly the H1N1 and H3N2 subtypes, pose ongoing threats to the swine industry and global public health. Current commercial vaccines generally provide limited cross-protection against heterologous viruses due to the frequent antigenic drift and shift in SIVs, highlighting the need for broad-spectrum vaccines. Self-assembling nanoparticles (NPs) can elicit strong and broad immune responses, representing a promising platform for the development of broad-spectrum nanovaccines. In this study, two newly-screened conserved epitopes (H1-3 and H1-5) and (H3-1 and H3-3) in hemagglutinin (HA) of the H1 and H3 subtypes, along with a highly conservative matrix protein 2 ectodomain (M2e), were displayed on ferritin NP in cocktail and mosaic forms, respectively, and were designated MHF-cocktail (MHFc) and MHF-mosaic (MHFm) nanovaccines. Under a prime-boost immunization strategy in a mouse model, the MHFm nanovaccine induced a higher antigen-specific IgG mediated antibody dependent cellular cytotoxicity (ADCC) than the MHFc nanovaccine, and significantly enhanced antigen-specific multifunctional CD4⁺ and CD8⁺ T cell responses as well as cytotoxic T-cell activity. Enzyme-linked immunosorbent spot proliferation assays indicated that splenic lymphocytes generated following vaccination with the MHFm nanovaccine exhibited enhanced proliferative capacity and secreted higher levels of interleukin-4 (IL-4) and interferon-γ (IFN-γ) compared with those from the MHFc nanovaccine. In mice, MHFm nanovaccine provided complete cross-protection against lethal H1N1 and H3N2 SIV challenge, while MHFc nanovaccine offered partial cross-protection. This study provides a potential strategy for designing and developing cross-protective vaccines against H1N1 and H3N2 SIVs.Keywords
Funding Information
- National Natural Science Foundation of China (U23A20243)
This publication has 45 references indexed in Scilit:
- A novel method to assess antibody-dependent cell-mediated cytotoxicity against influenza A virus M2 in immunized murine modelsBiosafety and Health, 2024
- Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in miceInternational Journal of Biological Macromolecules, 2024
- Self‐Assembled Multiepitope Nanovaccine Provides Long‐Lasting Cross‐Protection against Influenza VirusAdvanced Healthcare Materials, 2023
- Ferritin self-assembly, structure, function, and biotechnological applicationsInternational Journal of Biological Macromolecules, 2022
- Continued evolution of the Eurasian avian-like H1N1 swine influenza viruses in ChinaScience China Life Sciences, 2022
- A biepitope, adjuvant-free, self-assembled influenza nanovaccine provides cross-protection against H3N2 and H1N1 viruses in miceNano Research, 2022
- Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoproteinComputers in Biology and Medicine, 2020
- Emergence of Eurasian Avian-Like Swine Influenza A (H1N1) Virus from an Adult Case in Fujian Province, ChinaVirologica Sinica, 2018
- Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding SiteCell, 2015
- Antigenic and genetic characterization of a European avian-like H1N1 swine influenza virus from a boy in China in 2011Archives of Virology, 2012